Results 61 to 70 of about 4,078 (132)

Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma

Clinical and Translational Radiation Oncology, 2020
Background: The combination of somatostatin receptor-directed peptide receptor radionuclide therapy (PRRT) in combination with external beam radiotherapy (EBRT) might prove a feasible treatment option in patients with advanced meningioma.
Philipp E. Hartrampf, Heribert Hänscheid, Olivia Kertels, Andreas Schirbel, Michael C. Kreissl, Michael Flentje, Reinhart A. Sweeney, Andreas K. Buck, Bülent Polat, Constantin Lapa   +9 more
doaj   +1 more source

Prevalence of hitherto unknown brain meningioma detected on 68Ga-DOTATATE positron-emission tomography/computed tomography in patients with metastatic neuroendocrine tumor and exploring potential of177Lu-DOTATATE peptide receptor radionuclide therapy as single-shot treatment approach targeting both tumors

World Journal of Nuclear Medicine, 2019
There is a relative paucity of data in the literature regarding the prevalence of meningiomas and their detection in the clinical setting of neuroendocrine tumors (NETs).
Rahul V Parghane, Sanjay Talole, Sandip Basu   +2 more
doaj   +1 more source

Pathological complete response of initially unresectable multiple liver metastases achieved using combined peptide receptor radionuclide therapy and somatostatin analogs following pancreatic neuroendocrine tumor resection: a case report

Surgical Case Reports
Background Peptide receptor radionuclide therapy (PRRT) serves as a novel and effective treatment option for somatostatin receptor-positive unresectable liver metastases of pancreatic neuroendocrine tumors (PNETs).
Ryosuke Umino, Satoshi Nara, Noritoshi Kobayashi, Takahiro Mizui, Takeshi Takamoto, Daisuke Ban, Minoru Esaki, Nobuyoshi Hiraoka, Kazuaki Shimada   +8 more
doaj   +1 more source

Paltusotine versus octreotide: different effects on radioligand uptake in neuroendocrine tumours

Endocrine Oncology
Objective: Somatostatin receptor analogues are well-established in the treatment of metastatic gastro-enteropancreatic neuroendocrine tumours (GEP-NETs), especially for symptom control in patients with the carcinoid syndrome, and to control tumour growth.
Katharina Wang, Christoph J Auernhammer, Simon Lindner, Mathias Zacherl, Rudolf A Werner, Julian Maurer, Lea Peischer, Julia Hamati, Maximilian P Hungbauer, Thomas Knösel, Astrid Reul, Elena Kuzmenko, Diana Vetter, José Oberholzer, Umberto Maccio, Felix Beuschlein, Martin Reincke, Constanze Hantel, Karel Pacak, Ashley B Grossman, Kathrin Zitzmann, Svenja Nölting   +21 more
doaj   +1 more source

Succinate dehydrogenase-related pheochromocytoma and paraganglioma (SDHx-PPGL): clinical and genetic insights from an Indian study

Endocrine Connections
Objective: Data on succinate dehydrogenase-related pheochromocytoma and paraganglioma (SDHx PPGL) in India are limited. We describe the clinical and genetic characteristics of SDHx PPGL from a single center in western India.
Ketki Sunil Ambulkar, Anima Sharma, Vijaya Sarathi, Saba Samad Memon, Anurag Ranjan Lila, Rohit Barnabas, Manjiri Karlekar, Virendra Patil, Samiksha Hegisthe, Gwendolyn Fernandes, Sameer Rege, Gaurav Malhotra, Hemangini Thakkar, Nalini S Shah, Tushar R Bandgar   +14 more
doaj   +1 more source

Clinical Experience with Targeted Alpha-Emitter Peptide Receptor Radionuclide Therapy (α-PRRT) for Somatostatin Receptor-Positive Neuroendocrine Tumors

Pharmaceuticals
Background: α-emitting Peptide Receptor Radionuclide Therapy (α-PRRT) is emerging as a promising new generation of PRRT for neuroendocrine tumors (NETs), providing enhanced tumor cell cytotoxicity and reduced irradiation of adjacent healthy tissues due ...
Hannes Leupe, Merel Cauwenbergh, Frederik Cleeren, Jeroen Dekervel, Chris Verslype, Christophe M. Deroose   +5 more
doaj   +1 more source

Meeting Notes of the Taiwan Neuroendocrine Tumor Society & Taiwan Society of Nuclear Medicine Joint Conference - Peptide Receptor Radionuclide Therapy Targeting for Gastroenteropancreatic Neuroendocrine Tumors: Basic Principles and State-of-the-art Clinical Practice

Journal of Cancer Research and Practice
Objective: The current study aimed to investigate the basic principles and clinical applications, including the selection of proper candidates, follow-up strategies, and radiation protection issues relating to peptide receptor radionuclide therapy (PRRT).
Mei-Fang Cheng, Chih-Chieh Yen, Jeng-Shiun Du, Yu-Li Chiu, Ming-Huang Chen, Hui-Jen Tsai, I-Chen Wu, Hueng-Yuan Shen, Ruoh-Fang Yen, Li-Tzong Chen, On Behalf of Taiwan Neuroendocrine Tumor Society and Taiwan Society of Nuclear Medicine   +10 more
doaj   +1 more source

Peptide receptor radionuclide therapy for ectopic Cushing’s syndrome caused by metastatic neuroendocrine neoplasms

Endocrine Oncology
Background: Metastatic gastroenteropancreatic neuroendocrine neoplasms (GEPNEN) can cause ectopic Cushing’s syndrome (ECS). ECS is highly morbid and medical therapy is complex and can be ineffective.
Emma Boehm, Terry Hung, Tim Akhurst, Ramin Alipour, Cherie Chiang, Rodney J Hicks, Michael S Hofman, Aravind S Ravi Kumar, Nirupa Sachithanandan, Javad Saghebi, Michael Michael, Grace Kong   +11 more
doaj   +1 more source

Towards Effective Targeted Alpha Therapy for Neuroendocrine Tumours: A Review

Pharmaceuticals
This review article explores the evolving landscape of Molecular Radiotherapy (MRT), emphasizing Peptide Receptor Radionuclide Therapy (PRRT) for neuroendocrine tumours (NETs).
Paul M. D. Gape, Michael K. Schultz, Graeme J. Stasiuk, Samantha Y. A. Terry   +3 more
doaj   +1 more source

Clinical Outcomes of Peptide Receptor Radionuclide Therapy in Japanese Patients with Metastatic Rectal Neuroendocrine Tumors. [PDF]

Cancers (Basel)
Iizuka T, Kobayashi N, Wild D, Kaul F, Suzuki H, Maehara K, Okubo N, Tsuyuki S, Takano S, Kurita Y, Yoneda M, Ichikawa Y.   +11 more
europepmc   +1 more source